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A  consensus  multiplex  real-time  PCR  test  (PT13-RT)  for the oncogenic  human  papillomavirus  (HPV)  types
16, 18,  31,  33, 35,  39,  45, 51,  52, 56, 58,  59 and  66  is described.  The  test  targets  the  L1 gene.  Analytical  sen-
sitivity  is  between  4 and  400  GU (genomic  units)  in  the  presence  of  500  ng  of  human  DNA,  corresponding
to  75,000  human  cells.  HPV  types  are  grouped  into  multiplex  groups  of 3 or  4 resulting  in  the  use of  4
wells  per  sample  and  permitting  up to  24  samples  per  run  (including  controls)  in a standard  96-well
real-time  PCR  instrument.  False  negative  results  are  avoided  by  (a)  measuring  sample  DNA  concentra-
tion  to control  that  sufﬁcient  cellular  material  is present  and  (b)  including  HPV  type  6  as  a  homologousigh-risk HPV
eal-time PCR
ervical cancer
ervical screening
internal  control  in  order  to detect  PCR  inhibition  or competition  from  other  (non-oncogenic)  HPV  types.
Analysis  time  from  refrigerator  to  report  is 8 h, including  2.5  h hands-on  time.  Relative  to  the HC2 test,
the sensitivity  and  speciﬁcity  were  respectively  98% and  83%,  the  lower  speciﬁcity  being  attributable  to
the higher  analytical  sensitivity  of PT13-RT.  To  assess  type  determination  comparison  was  made  with
a reversed  line-blot  test.  Type  concordance  was  high  ( =  0.79)  with  discrepancies  occurring  mostly  in
s.multiple-positive  sample
. Introduction
Human papillomavirus (HPV) infection is the primary cause
f cervical cancer (Walboomers et al., 1999). Of the 118 types
escribed by de Villiers et al. (2004) 13 have been conﬁrmed as
eing oncogenic in genital mucosa (IARC, 2007).
HPV testing has been shown to have a higher sensitivity for high-
rade cervical dysplasia than the Papanicolaou test, although the
peciﬁcity is lower due to the high prevalence of benign, transient
PV infections (Cuzick et al., 2006). Many countries have adopted
PV testing as a secondary screening (triage) test for low-grade and
quivocal dysplasia (Wright et al., 2002; Waage, 2005) and its use
n primary screening has also been suggested (Dillner et al., 2008).
he HPV test used most widely is the Qiagen/Digene hybrid capture
HC2) test. HC2 is commercially available worldwide, straightfor-
ard to perform and interpret, and supported by a large body of
cientiﬁc literature making it the baseline against which other tests
re compared. The HC2 test classiﬁes the HPV types detected as
Abbreviations: HPV, human papillomavirus; GU, genomic units; LNA, locked
ucleic acid; MGB, minor groove binder; HC2, hybrid capture test.
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high-risk or low-risk, without more detailed genotyping. Where
genotyping is required more sophisticated tests based on nucleic
acid ampliﬁcation are required.
There are several advantages to genotyping: it distinguishes
benign serial transient infections from type-speciﬁc persistent
infections which have a high probability of neoplastic pro-
gression; it distinguishes HPV types of differing oncogenic
potential (Schiffman et al., 2005); and it provides epidemiological
information which will be of particular value in monitor-
ing the population effects of vaccination against HPV 16 and
HPV 18.
Genotyping tests that cover the full range of oncogenic HPV
types are available commercially but all the currently available
tests involve post-PCR sample handling which necessitates strin-
gent, labour- and resource-intensive molecular hygiene procedures
to prevent carry-over contamination. This limits the applicability
of such tests in the routine laboratory.
With the aim of providing a more rapid, less labour-intensive
HPV typing test that operates in a closed system, a quantitative
real-time PCR method using consensus primers and multiplexed
type-speciﬁc 5′-hydrolysis probes was developed. This test, allows
sensitive and speciﬁc detection and typing of the 13 oncogenic
HPV types HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and
Open access under CC BY-NC-ND license.66. Using standard 96-well instrumentation, clinical samples may
be analysed in batches of up to 22 and the entire analysis, including
sample processing and reporting can be completed in one working
day.
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Table 1
Probes for reverse line blot analysis.
Target Sequence
HPV 16 CTGCAAATTTAGCCAGTTCAAA
HPV 18 GCTTCACCTGGCAGCTGTGT
HPV 31 GGCTCCGGTTCAACAGCTAC
HPV 33 TGCCTCTATTCAAAGCAGTGC
HPV 35 GGTACCACTGGCACATTG
HPV 39 GGCACAGATATACGTGCAAA
HPV 45 GGCACTAGCGCTAATATGC
HPV 51 GTAGTGGTAATGGCCGTG
HPV 52 GGGTCTAACTCTGGCAATA
HPV 56 GGTAGCAATGGTAGAGAAC
HPV 58 GGTCCGGTAATACTGCAG46 A. Jenkins et al. / Journal of Viro
. Materials and methods
.1. Human DNA
All solutions of HPV control DNA were diluted to the appropri-
te concentrations in a 100 ng/l solution of human DNA (Sigma
4642, Sigma–Aldrich, St. Louis, MI)  in 1× TE buffer (10 mM Tris,
 mM EDTA pH 8.0) in order to mimic  the composition of a cell-rich
linical sample as closely as possible.
.2. Plasmids
Plasmids containing entire HPV genomes were provided by John
rrand with the permission of Lutz Gissmann (HPV 6, 11, 16 and
8), Gerard Orth (HPV 33 and HPV 39), Attila Lorincz (HPV 31, 35,
5, 52 and 56), Saul Silverstein (HPV 51) and Toshihaki Matsukara
HPV 58 and 59). Plasmids were transformed into Escherichia coli
H5-alpha and isolated by caesium chloride density gradient cen-
rifugation (Sambrook et al., 1989) or Qiagen HiSpeed Midi Kit
Qiagen GmbH, Hilden, Germany). DNA concentrations were deter-
ined by ultraviolet spectrophotometry (Sambrook et al., 1989).
he HPV 66 plasmid was a synthetic sequence corresponding to
ucleotides 6320–6600 in the HPV 66 genome (U31794) cloned
nto pUC57, synthesised by Genscript Corporation, Scotch Plains,
J. Ten-fold serial dilutions of plasmid DNA in 100 ng/l  human
NA were prepared in order to provide concentrations appropriate
or experimental use.
.3. Clinical samples
Were cervical cytobrush samples sent to Unilabs Telelab from
linical practises in Southeastern Norway for routine HPV analysis
ubsequent to ﬁndings of low-grade dysplasia, equivocal cytology
r inadequate sample according to Norwegian guidelines (Waage,
005). Samples were collected and transported in CYTYC thin prep
ransport medium (CYTYC, Crawley, UK) according to the manu-
acturer’s recommendations. 10 ml  of sample was centrifuged at
000 rpm for 10 min, the pellet was resuspended in 100 l phos-
hate buffered saline and DNA was extracted using the MagNAPure
utomatic DNA extraction instrument with the MagNAPure LC DNA
xtraction kit (Roche Diagnostics, Penzberg, Germany). DNA con-
entration was measured by determining A260 and A280 using
he Eppendorf Biophotometer (Eppendorf AG, Hamburg, Germany)
ccording to the manufacturer’s instructions. Samples yielding DNA
oncentrations < 5 ng/l were considered to contain too little mate-
ial and rejected. Samples (N = 206) were tested by hybrid capture
est, PT13-RT and reverse line-blot analysis.
.4. Hybrid Capture test
The Digene Hybrid Capture (HC2) test (Digene, Gaithersburg,
D)  was performed using 10 ml  of sample according to the manu-
acturers’ instructions.
.5. Reverse line-blot analysis
Biotin-labelled amplicons were generated using primers PTf
nd 5′ biotin-labelled PTrGr3 (see Table 2), which were designed
o have broad speciﬁcity for mucosal HPV types and which were
ound (data not shown) to amplify all the oncogenic HPV types tar-
eted in the real-time PCR reaction. PCR reactions were run in a
0 l volume containing 5 l of sample DNA in an ABI Prism 7000
equence Detection System (Applied Biosystems, Foster City, CA,
SA) using DyNAmo SYBR green qPCR mix  with ROX passive con-
rol dye (Finnzymes, Espoo, Finland) and the standard PCR program
escribed in Section 2.8.  Sample quality was controlled by a parallelHPV 59 GGTACTGACATACGTGCC
HPV 68 GGCACTGACATACGTGACA
ampliﬁcation of the human globin gene (Saiki et al., 1985) under the
same reaction conditions. Denaturation proﬁles from 60 to 91 ◦C
(temperature increment 1.75 ◦C/min) were obtained and melting
temperatures were determined by the position of peaks in the ﬁrst
derivative plot using the software provided with the instrument.
The success of -globin PCR was assessed according to the presence
of a denaturation peak at 81 ◦C.
5′ amino-labelled probes (MWG  Biotech, Ebersburg, Germany)
were bound to carbodiimide-activated nylon membranes (Pall Bio-
dyne C, Pall Europe Ltd., Portsmouth, UK) as described previously
(Schouls et al., 1999). Each probe was  applied in two 2 mm parallel
stripes of 100 and 200 pmol respectively using a lineblot manifold
(Miniblotter MN45, Immunetics, Cambridge MA,  USA). The probes,
which were selected from regions of high intertypic variability
without known intratypic polymorphism, are listed in Table 1.
10 l aliquots of ampliﬁed samples supplemented with tracer
dye (0.03% bromophenol blue, 0.03% xylene cyanol, 0.4% Orange
G, 15% Ficoll-400, 2 mM Tris–HCL pH 7.5, 50 mM EDTA pH 8.0)
were diluted in 150 l 2× SSPE, 0.1% SDS (2× SSPE is 0.3 M NaCl,
0.02 M NaH2PO4, 0.2 M EDTA), denatured at 99 ◦C for 10 min  then
placed immediately on ice. 140 l of sample was applied in the
Miniblotter MN45 with the sample channels running perpendicu-
lar to the probe stripes. The apparatus was sealed and incubated
overnight at 45 ◦C. After aspiration of samples and washing of the
sample channels the apparatus was  disassembled and the ﬁlter
was washed twice in 2× SSPE, 0.5% SDS for 10 min  at 50 ◦C, then
incubated in 10 ml  2× SSPE, 0.5% SDS containing 2.5 l (3.75 mU)
streptavidin–peroxidase conjugate (Roche Molecular Biochemi-
cals, Mannheim, Germany) for 30 min  at 42 ◦C with rotary mixing.
After washing twice in 2× SSPE, 0.5% SDS for 10 min  at 42 ◦C and
two brief rinses in 2× SSPE at 42 ◦C amplicon detection was  per-
formed using the Amersham ECL system (Amersham Biosciences,
Piscataway, NJ, USA) using a 10 min  ﬁlm exposure.
2.6. Primer design
The PCR primers (see Table 2) were designed to target conserved
regions of the L1 gene corresponding to positions 6348–6373 and
6556–6579 in the HPV 16 genome (K02718). A sequence similarity
tree of the concatenated primer target sequences provided the
initial basis for the grouping of the target types (HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66, plus the inter-
nal control, HPV 6) into four primer target sequence similarity
groups. A distance tree of these sequences was constructed using
CLUSTALW (http://www.ebi.ac.uk/Tools/clustalw2/index.html).
The initial groups were: HPV 18, 45, 52 and 59; HPV 39, 51, 56
and 66; HPV 16, 33 and 58; and HPV 31, 35 and HPV 6. A single
forward primer, PTf was found to be suitable for all groups. Reverse
primers were optimised for each group. Variable positions were
accommodated by using inosine as a wildcard base, thymine as a
A. Jenkins et al. / Journal of Virological Methods 187 (2013) 345– 351 347
Table 2
Composition of the multiplex PCR mixes.
Target Type Sequence Label Concentration
Group 1
Primers
PTf Consensus TGYAAATATCCWGATTATWTIIAAATG 600 nM
PTrGr1b Group 1 TGTAGCCAGTATGGYTTATTGAA–3 600 nM
Probes
PTp18(131) HPV 18 MGB  ACTGTGCCTCAATCC FAM 150 nM
PTp52(4) HPV 52 LNA TC+TAA+CTC+TGGC+AA+TAC+TGC ROX 50 nM
PTp59(1) HPV 59 MGB  TACTGACATACGTGCC NED 100 nM
Group  2
Primers
PTf Consensus TGYAAATATCCWGATTATWTIIAAATG 600 nM
PTrGr2 Group 2 TGKAGCCAATAAGGTTTATTAAA 600 nM
Probes
PTp  39(4) HPV 39 LNA CA+CA+GATAT+ACG+TG+CAA+ACC ROX 50 nM
PTp  51(156) HPV 51 MGB  AGTGGTAATGGCCGTGAC FAM 100 nM
PTp  56(2) HPV 56 MGB  CAATACCTGCAGAGTTATA VIC 50 nM
PTp  66 (1) HPV 66 MGB  TTGGAAGGGTGGCAAT NED 100 nM
Group  3
Primers
PTf Consensus TGYAAATATCCWGATTATWTIIAAATG 600 nM
PTrGr3 Consensus TGIAICCAATAIGG(CT)TTATTGAA 600 nM
Probes
PTp16(6) HPV 16 MGB  ATTTGCAGTAGACCCAGAG FAM 150 nM
PTp45(6) HPV 45 MGB  GTGAAACCCCTGGCAGT VIC 150 nM
PTp58 HPV 58 MGB TCCGGTAATACTGCAG NED 50 nM
Group  4
Primers
PTf Consensus TGYAAATATCCWGATTATWTIIAAATG 600 nM
PTrGr4 Group 4 TGTAICCAATATGGtTTATTAAA 600 nM
Probes
PTp  31 HPV 31 MGB TCCGGTTCAACAGCTAC VIC 50 nM
PTp  33(9) HPV 33 LNA TG+CCTCTATT+CAAAG+CAGTGC ROX 50 nM
PTp  35(4) HPV 35 MGB  GTACCACTGGCACATTG FAM 100 nM
PTp  6(154) HPV 6* MGB  TAGTGGAAATCGCACGTCT NED 50 nM
Oligonucleotide composition of the multiplex mixes. Degeneracies are indicated by IUPAC ambiguity codes. I indicates inosine. LNA residues are indicated by a “+” before the
designated nucleotide. FAM, NED, ROX and TaqMan are registered trademarks of Life Technologies Inc. LNA is a registered trademark of Exiqon Life Sciences.
Fig. 1. Alignments of primers and their target sequences. A period (“.”) indicates identity to the reference sequence. IUPAC ambiguity codes indicate variant positions in the
target  sequence and mixed nucleotides in the primer sequences. I indicates inosine. For the reverse primers the plus strands of the target sequences is shown along with the
reverse  complement (rc) of the primer sequence; the primer sequence itself is shown in reverse orientation (3′–5′).
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niversal pyrimidine, guanine as a universal purine (exploiting the
tability of the noncanonical G:T basepair), incorporating mixed
ucleotides or allowing the mismatch. Later, it was found to be
xpedient to modify the composition of the groups to group 1:
PV 18, 52 and 59; group 2: HPV 39, 51, 56 and 66; group 3: HPV
6, 45 and 58; and group 4: HPV 31, 33, 35 and 6. This could be
chieved without modifying primer sequence as the conserved
equences of the primer targets allow most types to be ampliﬁed
fﬁciently by more than one of the primer pairs. Fig. 1 shows the
rimer sequences along with their target sequences using the
nal group composition. Primers were obtained from Eurogentech
Herstal, Belgium). It should be noted that the group 3 primer
TrGr3 is a consensus reverse primer for all targeted HPV types; a
rimer targeting group 3 speciﬁcally was tested but was found not
o improve performance.
.7. Probe design
TaqMan MGB  probes were designed using Primer Express
oftware (Applied Biosystems, Foster City, CA) using the tar-
et amplicon as input sequence and specifying an amplicon
ength of ≥200 bp. As Primer Express will not select probes
nless it can also ﬁnd a primer pair that satisﬁes its internal
esign criteria it was sometimes necessary to facilitate the pro-
ess by bracketing the input sequence with the ‘primer-friendly’
equences GACAATTCTGCCATGCGACAT and CGATTCACGGTTTC-
ATATCG. Candidate probes were screened by comparison with a
LUSTALW multiple sequence alignment of the amplicon region
f the target HPV types with intratypic variant positions marked.
robe sequences were selected if they targeted a sequence that was
ighly speciﬁc for the target type and contained no intratypic poly-
orphisms. TaqMan MGB  probes were labelled with FAM, VIC or
ED and obtained from Applied Biosystems. All MGB  probes incor-
orate a dark quencher. Probes suitable for labelling with ROX
ere either (a) MGB  probes redesigned as LNA probes with the
elp of Sigma Genosys, (Cambridge, UK) and http://lna-tm.com/
r (b) designed as non-MGB TaqMan probes using Primer Express.
OX-labelled probes were ﬂuorophor-labelled at the 5′ end and
uenched with the dark quencher BHQ2 at the 3′ end. All probes
ere designed to have a Tm of 70 ± 2 ◦C.
.8. PCR program
For all experiments the PCR program was: 95 ◦C, 12 min  followed
y 45 cycles of 95 ◦C, 15 s; 45 ◦C, 30 s; 60 ◦C, 60 s. For experiments
sing SYBR green, dissociation analysis was appended to the end
f the program. All PCR reactions were run on the ABI Prism 7000
r 7300 genetic analyzer (Applied Biosystems, Foster City, CA) with
he ROX passive reference function disabled in order to allow the
OX colour channel to be used for probe detection. As the com-
osition of the mastermix may  affect the emission spectra of the
uorophors, spectral calibrations were performed with solutions of
nquenched ROX-, NED-, FAM- and VIC-labelled oligonucleotides
or each of the PCR mastermixes used in order to ensure optimal
hannel separation.
.9. Testing of primers
Primer testing was performed by amplifying 10-fold serial dilu-
ions of the target HPV types using Finnzymes DyNAmo SYBR green
PCR kit F400 (Finnzymes, Espoo, Finland). The criterion for primer
cceptability was an analytical sensitivity of 4000 genomic units
GU) or better for all target HPV types. Analytical sensitivity was
eﬁned as the lowest target concentration that gave an unequivocal
ype-speciﬁc dissociation peak.l Methods 187 (2013) 345– 351
2.10. Probe screening and titration
Probes were screened at a concentration of 200 nM by ampli-
fying 10-fold serial dilutions of the target HPV type and the
appropriate primer pair in Finnzymes DyNAmo probe PCR kit F450
(Finnzymes, Espoo, Finland) or, in later experiments, PerfeCta qPCR
FastMix, UNG (Quanta Biosciences, Gaithersburg, MD). A positive
ampliﬁcation signal from 400 GU of target DNA was the minimum
criterion for approval of the probe for further testing.
Probe titration was  performed in order to determine the min-
imum concentration that could be used without loss of analytical
sensitivity; probe concentrations tested were 200, 150, 100 and
50 nM.  Target DNA concentrations that bracketed the cut-off con-
centration determined previously for 200 nM probe were used.
2.11. Testing of probes in multiplex
For multiplex testing, the probes were combined at the mini-
mum  acceptable concentration determined by probe titration and
tested against dilution series of all members of the target group.
Criteria for acceptance of a multiplex combination were analyt-
ical sensitivity 400 GU or better for all types and no intra-group
cross-reactions. Where unacceptable loss of analytical sensitivity
or cross-reaction was detected, reactions were repeated with fewer
probes in all combinations in order to identify the interfering probe,
which was  replaced with a new candidate.
Successful groups of probes were tested against 4 × 104 GU of
each of the 13 targeted HR HPV types and the internal control,
HPV 6 in order to detect cross-reaction. Where cross-reaction
was observed, the cross-reacting probe was tested against the
cross-reacting HPV type(s) in a simplex reaction. Cross-homology
was tested using the LALIGN program available on the Swiss
EMBNet node (http://www.ch.embnet.org). Several probes that
cross-reacted only in multiplex and lacked signiﬁcant homology
to the cross-reacting type were encountered.
Where probes were rejected due to interference or cross-
reaction, new probes were designed and tested as described in
Sections 2.10 and 2.11. 1–3 rounds of reformulation were required
to arrive at the multiplex formulations described in Table 2. These
formulations were used in all subsequent experiments.
2.12. Controls
For each multiplex group a positive control containing a mixture
of the targeted HPV types was run in parallel. The concentrations
used were 40,000 GU/5 l (HPV 52, 39 and 66); 4000 GU/5 l (HPV
16, 18, 31, 33, 35, 45, 56, 58 and 59) or 400 GU/5 l (HPV 51).
The non-oncogenic HPV type HPV 6 was used as an internal con-
trol against PCR inhibition. HPV 6 was  added at a concentration of
4 × 103 GU per reaction to all multiplex group 4 reactions.
3. Results
3.1. Analytical sensitivity
Analytical sensitivity was determined by ampliﬁcation of 10×
serial dilutions of the target HPV types using the multiplex formu-
lations shown in Table 2. In the presence of 500 ng of human DNA,
the detection cut-off was  4 GU (genomic units) for HPV 31 and HPV
51; 40 GU for HPV 16, HPV 18, HPV 39, HPV 56 and HPV 59; and
400 GU for HPV 33, HPV 35, HPV 45, HPV 52, HPV 58 and HPV 66.
Lowering the amount of human DNA to 50 ng resulted in a detection
cut-off of 4–40 GU for all types.
In order to control that the analytical sensitivities deter-
mined using plasmid clones diluted in human DNA obtained from
commercial sources are applicable to clinical samples processed
A. Jenkins et al. / Journal of Virological Methods 187 (2013) 345– 351 349
Table 3
Comparison of HC2 and PT13 real-time testing of clinical samples.
HC2 N
+ +/− −
PT13-RT
+ 59 7 23 89
−  1 0 115 116
Inhibitory 1 0 0 1
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tion. In all cases the original interpretation of the PT13-RT test was
conﬁrmed.
Table 4
Comparison of typing results between PT13-RT and reverse line blot.
Description N Remarks
Identical results
Both negative 111
Both positive, single type 44
Both positive, multiple types 7
Identical results, total 162
Discrepant results
RLB negative, PT13-RT positive 12 Cq ≥ 30 (N = 12); HPV 52 or 56
(N  = 7); inhibitory sample
(N = 1); equivocal result, RLB
(N = 2)
RLB positive, PT13-RT negative 3
RLB single positive, PT13-RT
multiple positive
12 Cq ≥ 30 and/or HPV 52 or 56
(N = 9)
Multiple types, type agreement
partial
13N 61  
ccording to the test protocol, the following tests were performed:
1) substitution of human DNA from commercial sources with DNA
rom clinical samples as diluent; (2) spiking of clinical samples with
erial dilutions of CaSki cells and (3) re-extraction of selected serial
ilutions of DNA using the MagNAPure instrument.
Substituting the human DNA diluent from commercial sources
100 ng/l) with pooled DNA from clinical samples (50 ng/l) gave
nchanged cut-off values for all HPV types. Cq values were up to +2
ycles higher (mean = 0.6 cycles) suggesting that DNA from some
linical samples may  have a slight inhibitory effect on the reaction.
When doubling dilutions of CaSki cells were diluted in pooled
PV-negative human cervical samples and extracted according to
he standard protocol, HPV16 was detected down to the theoretical
imit of 1 CaSki cell per 10 ml  aliquot, showing that intracellular HPV
NA is recovered from and detected in cervical samples efﬁciently.
In order to test recovery of HPV DNA in the MagNAPure DNA
xtraction process 10 l of a plasmid dilution of each target HPV
ype one log10 above cut-off was diluted with 90 l of PBS and
xtracted according to the standard protocol. The ﬁnal volume after
xtraction was 100 l. All HPV types were detected also after re-
xtraction. Cq values were on average +0.7, which corresponds to a
0% reduction in HPV concentration assuming 100% PCR efﬁciency.
his indicates that HPV is recovered with at least 60% efﬁciency.
.2. Internal control
In order to provide an internal control a plasmid containing the
enome of HPV6 was added to all group 4 reactions. In order to
etermine suitable concentrations HPV6 was added to the group
 mastermix at varying concentrations and the mix  was used to
etect HPV31, HPV33 and HPV35 at the cut-off concentrations
etermined previously. It was found that HPV 6 could be added
o the group 4 multiplex reactions at levels of 400–4000 GU per
eaction without compromising the analytical sensitivity for HPV
1, HPV 33 or HPV 35. 4000 GU per reaction was  chosen as standard
oncentration for the internal control.
.3. Clinical samples
Table 3 compares the results of the PT13-RT test with those of
he HC2 test for 206 clinical samples. Of 61 samples that were pos-
tive by HC2, 59 were PT13RT positive, one was inhibitory and one
as negative, giving a sensitivity of 98% relative to HC2. Of 138 sam-
les negative by HC2, 115 were negative by PT13-RT and 23 were
ositive, giving a speciﬁcity of 83% relative to HC2. Of these latter
1/23 had Cq values >30, indicating low viral loads. By contrast, of
he 59 HC2+/PT13-RT+ samples, only four had Cq values >30. This
uggests that the discrepancies are due principally to the analytical
ensitivity difference between the PT13-RT and HC2 tests. The HPV
ypes detected in the discrepant samples were HPV16, 18, 45 and
1 (four samples each), HPV 31, 52 and 56 (two samples each) and
PV 58 (one sample).
Discrepancy analysis was performed using the Roche Amplicor
800 HPV test. Discrepancy analysis conﬁrmed the PT13-RT result7 138 206
in 50% (12/24) of discrepant samples, including the single sample
that was positive by HC2 and negative by PT13-RT. Five of the con-
ﬁrmed samples as against none of the non-conﬁrmed samples were
HPV16 positive. Apart from this there was no apparent difference in
type distribution between conﬁrmed and non-conﬁrmed samples.
In order to assess the accuracy of typing, a second typing test
using reverse line blot (RLB) was performed. In the reverse line
blot test ampliﬁcation is performed with the consensus group 3
primers but different probes are used. Two  hundred and two sam-
ples were tested. The overall kappa value (Fleiss et al., 2003) for the
12 types common to both tests (HPV types 16, 18, 31, 33, 35, 39,
45, 52, 56, 58 and 59) was  0.79. One hundred and sixty-two sam-
ples gave identical results with both tests: 111 were negative; 44
were positive for a single HPV type and seven were positive for 2
or 3 types. Three samples were positive only by RLB; one of these
was partially inhibitory and in the other two the RLB hybridisa-
tion signal was weak and equivocal. Twelve samples were positive
only by PT13-RT. All had high Cq values (≥30) and seven contained
HPV 52 or HPV 56, for which the RLB test has a reduced sensitivity.
In 12 samples PT13-RT detected an extra type in a sample where
RLB detected only one; in nine of these samples the extra type was
HPV 52 or 56 and/or had a Cq value ≥30. Thirteen samples were
multiply-positive by both tests but the combination of types agreed
only partially. Four had extra types detected only by PT13-RT, ﬁve
had extra types detected only by RLB and four had extra types in
both tests (Table 4).
In cases where discrepancies were found or where correct inter-
pretation seemed in doubt the PCR was  repeated in a simplex
format with only the probe appropriate to the HPV type in ques-Discrepant results, total 40
N 202
Results for HPV 66 (not included in the RLB test) and HPV 68 (not included in PT13-
RT) are disregarded.
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.4. Logistic considerations
The time required for completion of the analysis is 8 h:4.5 h for
ample processing, 15 min  for PCR setup, 2.5 h PCR run time and
 h for analysis. Of this, 2.5 h is hands-on time. The batch size is 22
amples, plus controls.
. Discussion
The PT13-RT test detects and genotypes simultaneously the 13
ncogenic mucosal HPV types recognised in the 2007 IARC mono-
raph (IARC, 2007). The analytical sensitivity is 400 GU (genomic
nits) or better for all types. Since each test uses 1/20 of a 10 ml
ample, this corresponds to an analytical sensitivity per sample
f 8000 GU or better. This was determined using reconstructed
amples consisting of plasmid-cloned HPV genomic DNA diluted
n puriﬁed human DNA from commercial sources. Experiments
here the reconstructed samples were subjected to the protocol
xtraction process, where the human DNA diluent from commer-
ial sources was replaced with DNA from clinical samples, or where
linical samples were spiked with the HPV16-containing cell line
aSki, all conﬁrmed the analytical sensitivity estimates determined
n reconstruction experiments, indicating that they are likely to
e applicable to clinical samples. The background human DNA
oncentration in clinical samples is usually lower (10–40 ng/l)
han in the reconstruction experiments and, since lowering the
oncentration of human DNA is found to improve the analytical
ensitivity, the analytical sensitivity for real clinical samples is
xpected to be better. In the rare cases of samples yielding DNA
oncentrations of over 100 ng/l, dilution of the sample would be
ndicated. The analytical sensitivities reported here are comparable
o those reported by Moberg et al. (2003) for a multiplex real time
CR test for HPV which uses type-speciﬁc rather than consensus
rimers.
In clinical samples, PT13-RT had a 98% sensitivity and 83% speci-
city for HPV detection relative to the HC2 test. Since the HC2
est is not 100% speciﬁc for oncogenic HPV types (Poljak et al.,
002; Castle et al., 2002) and has a lower analytical sensitivity than
T13-RT this result is not unexpected; similar patterns of speci-
city and sensitivity have been seen when comparing PCR tests
ith the Hybrid Capture test (Molijn et al., 2005). Samples with
q values >30 (corresponding to low viral loads) comprised 91% of
he PT13-RT positive/HC2 negative samples but only 7% of PT13-RT
ositive/HC2 positive samples, which is consistent with differences
n analytical sensitivity causing the discrepancies. Third-test dis-
repancy analysis conﬁrmed the positive PT13-RT result in 11/23
amples. Discrepancy analysis for the single sample that was  pos-
tive by HC2 and negative by PT13-RT also conﬁrmed the PT13-RT
esult.
The accuracy of typing with the PT13-RT test was assessed by
omparison with a reverse line-blot (RLB) hybridisation test. Of the
9 samples that were positive for a single HPV type by RLB, the
ame type was detected by PT13-RT in 56 samples, with an addi-
ional type being detected in 12 of these samples. For the 20 RLB
ultiple-positive samples there was complete type agreement in
even samples and partial agreement in 13. In no case was there
omplete disagreement of type. The results were consistent with
 high degree of typing concordance ( = 0.79), but with PT13-RT
aving a higher sensitivity, particularly for HPV 52 and HPV 56.
revious experiments (data not shown) indicate that the RLB test
as a reduced analytical sensitivity for these types.The PT13-RT test is designed to be highly error-resistant, the
alient features being use of a closed-system real-time PCR for-
at, inclusion of an internal control and measurement of sample
NA concentration. These features minimise interference froml Methods 187 (2013) 345– 351
carry-over contamination, inhibition and sample insufﬁciency
respectively. In real-time PCR ampliﬁcation, detection and typing
occur simultaneously in a closed tube. There is thus no need for
handling ampliﬁed material and the risk of false positive results
caused by carry-over contamination is avoided. The internal con-
trol, HPV6 is ampliﬁed in the group 4 reaction and will be negative
if ampliﬁcation is inhibited by impurities in the sample or if there is
competition from large amounts of an ampliﬁable non-oncogenic
HPV type. However, samples that are strongly positive for an onco-
genic HPV type can, and do, out-compete the internal control.
A positive result thus takes precedence over the internal con-
trol result, which is relevant only if no oncogenic HPV types are
detected. Finally, measuring DNA concentration by UV spectropho-
tometry provides a simple way  to check that the sample contains
sufﬁcient cellular material and has yielded sufﬁcient DNA for a reli-
able result to be obtained. Inter-genotype competition is the main
residual source of error and may  affect the combination of geno-
types detected in samples containing more than one genotype,
particularly where the viral loads are very unequal. Most typing
discrepancies observed in this study were in multiple-positive sam-
ples.
The PT13-RT test is intrinsically semi-quantitative since results
are read off as Cq values which are proportional to the initial con-
centration of target DNA. It would also be possible to run the
reaction in a fully quantitative mode by including dilution series of
the target type(s) in order to construct standard curves. The quanti-
tative nature of the test has several advantages. In epidemiological
studies it would be possible to establish a constant cut-off value
for all types, thus eliminating the biased prevalence estimates that
can result from type-speciﬁc differences in analytical sensitivity. In
clinical use the viral load may  be determined; clinical value of viral
load measurements remains a matter of ongoing research, viral load
is reported to be correlated with disease severity for HPV 16 but not
for HPV 18 (Woodman et al., 2007). The PT13-RT test would allow
viral load cut-off values to be established on a type-speciﬁc basis as
type-speciﬁc clinical data become available. It has been suggested
(Schiffman et al., 2000) that the HC2 test owes its higher speciﬁcity
for cervical dysplasia relative to PCR tests to its relatively low ana-
lytical sensitivity. By adjusting cut-off values for the PT13-RT test
it would be possible to conﬁgure the test to mimic the analytical
sensitivity of the HC2 test. Finally, use of a quantitative test may
be of use in following the progress of infections and the effects of
treatment.
In the present format of the test all stages of the analysis
including reporting results can be completed in 8 h, 2.5 h of which
is hands-on time; the batch size is 22 samples. By overlapping
runs, three runs per day could be achieved, which would utilise
the capacity of a single MagNAPure extractor and ABI7300 PCR
machine optimally. Incremental improvements in analysis time
could be achieved by optimising step times of the PCR program, by
using rapid cycling instruments and/or by employing faster DNA
extraction methods. Larger batches of samples could be analysed
using 384-well format real-time PCR instruments and 96-well DNA
extractors, both of which are now available on the market.
This test will be applicable in diagnostic, screening and research
applications where HPV genotyping and/or viral load estimates
are required and in epidemiological studies where unbiased type-
speciﬁc prevalence estimates are needed.
Conﬂicts of interestThe present test is the subject of Norwegian patent 330943, and
dependent patent applications worldwide held by the company
Allum-Jenkins AS, of which A.J. and A.G.A. are sole shareholders.
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